Journals / Glokom Katarakt / 2020 / Cilt: 29 - Sayı: 2

The Comparison of Bacterial Contamination and Antibacterial Effi cacy of the Anti-Glaucomatous Eyedrops with and without Preservatives

Pages
118–122
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Multi-dose preservative-free antiglaucomatous ophthalmic solutions have not any risk of bacterial contamination unless the tip of the bottle is contaminated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To investigate the bacterial contamination risks and antimicrobial activities of the preservative-free and preservative-containing anti-glaucomatous ophthalmic solutions.
📊
Key Findings & Data:Materials and Methods: Ophthalmic solution bottles of preservative-free brimonidine 0.15% (D1), benzalkonium chloride-containing (BAK) brimonidine 0.15% (D2), purite-containing brimonidine 0.15% (D3) and BAK-containing timolol maleate dorzolamide fi xed combination (D4) were included in this study in terms of microbial contamination risk.
💡
Conclusion & Impact:Conclusions: Multi-dose preservative-free antiglaucomatous ophthalmic solutions have not any risk of bacterial contamination unless the tip of the bottle is contaminated.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Purpose: To investigate the bacterial contamination risks and antimicrobial activities of the preservative-free and preservative-containing anti-glaucomatous ophthalmic solutions. Materials and Methods: Ophthalmic solution bottles of preservative-free brimonidine 0.15% (D1), benzalkonium chloride-containing (BAK) brimonidine 0.15% (D2), purite-containing brimonidine 0.15% (D3) and BAK-containing timolol maleate dorzolamide fi xed combination (D4) were included in this study in terms of microbial contamination risk. Moreover, microbial contamination of the two bottles [preservative-free brimonidine 0.15% (D7) and BAK-containing brimonidine 0.15% (D8)] was investigated after contacting their tips with the lower eyelid edge of a researcher. Every day twice a day for 60 days; the caps of the bottles were opened and they were closed after waiting for 20 sec. One drop was added from these six bottles 11 times during the study period (60 days) to the six separate and renewed blood-agar mediums. Microbial contamination was evaluated every visit by examining the blood agar mediums by the same microbiologist. In terms of antimicrobial effi cacy; D1, D2, D3 and D4 were compared with the antibiotic containing ophthalmic solutions; moxifl oxacin (D5) and tobramycin (D6) by using agar well diffusion method. Results: No bacterial growth was observed in the mediums of D1, D2, D3, D4 and D8 bottles. The bacterial growth of methicillin-susceptible and resistant coagulase-negative staphylococci was observed in the medium of D7 bottle on some days. A large inhibition zone was seen around D5 and D6, whereas a smaller inhibition zone was detected around D2 and D4. No inhibition zone was detected around the D1 and D3 bottles. Conclusions: Multi-dose preservative-free antiglaucomatous ophthalmic solutions have not any risk of bacterial contamination unless the tip of the bottle is contaminated.

🔖

Cite This Article

OZULKEN, K., CUBUK, M. O., INAN, N., ACAR, U., GOCMEN, J. S., AKMAN, A. (2020). The Comparison of Bacterial Contamination and Antibacterial Effi cacy of the Anti-Glaucomatous Eyedrops with and without Preservatives. Glokom Katarakt, Cilt: 29 - Sayı: 2, 118–122. https://ajindex.com/articles/226403

References (17)

  1. Kallings LO, Ringertz O, Silverstolpe L. Microbial contamination of medical preparations. Acta Pharm Suec. 1966;3:219-28
  2. Yıldırım N. Glokom ve Oküler Yüzey Glo-Kat 2014;9: 159- 66
  3. Rasmussen CA, Kaufman PL, Kiland JA. Benzalkonium chloride and glaucoma. J Ocul Pharmacol Ther. 2014;30:163- 9
  4. Aktas Z, Yolcu D, Cubuk MO. Glokomlu Olgularda Prostaglandin Analoglarının Korneal Sensitivite, Oküler Yüzey Değişiklikleri ve Hayat Kalitesi Üzerine Etkisi. GloKat 2013;8:83-88 5- Kim CY, Hong S, Seong GJ. Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther. 2007;23:481-6
  5. Baudoin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716-26
  6. Rahman MQ, Tejwani D, Wilson JA, et al. Microbial contamination of preservative free eye drops in multiple application containers. Br J Ophthalmol. 2006;90:139-41
  7. Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010 Jul;29:312-34
  8. Albietz JM, Bruce AS. The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments. Curr Eye Res. 2001;22:8-18
  9. Kaur IP, Lal S, Rana C, et al. Ocular preservatives: associated risks and newer options. Cutan Ocul Toxicol. 2009;28:93- 103
  10. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18:205-15
  11. Geyer O, Bottone EJ, Podos SM, et al. Microbial contamination of medications used to treat glaucoma. Br J Ophthalmol. 1995;79:376-9
  12. Jok DH, Wormser GP, Nichols NS, et al. Bacterial contamination of ophthalmic solutions used in an extended care facility. Br J Ophthalmol. 2007;91:1308-10
  13. Taşli H, Coşar G. Microbial contamination of eye drops. Cent Eur J Public Health. 2001;9:162-4
  14. Razooki R. A.,Saeed E.N., Aldeem H.I.O. Microbial Contamination of Eye drops in outpatient in Iraq. Iraqi J Pharm Sci, Vol.20, 2011: 91-95
  15. Birkhoff M and Marx D: New devices for dispensing ophthalmic treatments may be the key to managing the lifecycle of established products with low investments in fi lling technology. IPI, 2010, Spring edition:44-46
  16. Marchin I, Feuillolay C. Roques C. Unpreserved ophthalmic formula: PYCLEAR® Protection fully controlled risk of contamination with common 3 parts eyedropper, ARVO 2016 Annual Meeting, Abstract Number: 768-C0057
  17. Marx D, Birkoff M. Ophthalmic Squeeze Dispenser– Eli